Generic Drug Surveillance Could Be Enhanced By Dispensers Recording NDC, Manufacturer Data
US FDA’s MedWatch program could benefit from additional data capture – and generic and biosimilar reputations could too.
You may also be interested in...
Mallinckrodt and Kremers seem prepared to fight formal notice, which comes almost two years after FDA found their methylphenidate generics failed to demonstrate bioequivalence to the Janssen's brand drug.
Consortium’s biosimilar pharmacovigilance could provide data foundation to pressure FDA that suffixes are not needed in non-proprietary names.
As November deadline looms, firms experience better receiving, communications thanks to upgrades, but FDA still waiting.